In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 2b portion of the AZURE-1 study evaluating brelovitug, an ...
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus paclitaxel alone in the key secondary endpoint of ...
Some medical decisions do not come with a single clean answer. A doctor may know what disease a patient has, yet still face a ...
Carbon Core EMS ab stimulator 2026 availability: multi-zone belt, arm, and leg strap training system now offered ...
Albert Breer explains the supplemental draft process and shares some glowing recommendations from team evaluators: “His arm is electric.” ...
You log into your accounts and your apps, preferences, and contacts should sync to the new hardware. But in the world of ...
Roche’s BTK inhibitor, fenebrutinib, cuts relapse rates in patients with relapsing multiple sclerosis (RMS), but safety ...
How much water will be available in Lake O’ the Pines if an extreme drought strikes, and how must the cities that depend on ...
The agency’s prestigious research office spent decades doing scientific work insulated from political pressure. Now it’s ...
A paddle-wielding robot is so adept at playing table tennis that it is posing a tough challenge to elite human players and ...
MedPage Today on MSN
Stiff Person Syndrome Patients Regain Mobility After Single-Dose Cell Therapy
CAR-T therapy shows promise in clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results